PARIS--(BUSINESS WIRE)--Regulatory News: ExonHit Therapeutics S.A. (Paris:ALEHT) (Alternext: ALEHT) is pleased to announce that it has been chosen to participate in the European Innovative Medicines Initiative (IMI) consortium focused on identifying biomarkers for Alzheimer’s disease (PharmaCog).
